Statistics

Total Visits

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)106

Select a period of time:

Number of views in the range

Views
Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD)35

Views

Views
December 202517
January 20262
February 20261
March 20265
April 20268
May 20262
June 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil10
United States7
United Kingdom3
Germany2
Canada1
Denmark1
Ecuador1
Spain1
Ethiopia1
Finland1
 

Top cities views

Views
Addis Ababa1
Asunción1
Brasília1
Camaçari1
Campo Grande1
Canoas1
Coquitlam1
Cuauhtémoc1
Dakar1
Durban1